Related Experiment Video
Updated: Jul 21, 2025
Author Spotlight: Insights into Visual Cortex Research Through Wide-View fMRI Mapping
Published on: December 8, 2023
Pediatric Optic Pathway Gliomas Resource Utilization and Prevalence in the OptumLabs Data Warehouse
Theo N Stoddard-Bennett1, Fei Yu, Samuel J Spiegel
1Department of Ophthalmology (TNS-B, FY, ALC, SLP), Stein Eye Institute, University of California, Los Angeles, California; Department of Biostatistics (FY), University of California Los Angeles, Fielding School of Public Health, Los Angeles, California; Department of Ophthalmology (SJS), Gavin Herbert Eye Institute, University of California Irvine, Irvine, California; Department of Medicine Statistics Core (CFP), David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California; and Department of Ophthalmology (MXR), Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Background:
Although significant progress has been made in improving the rate of survival for pediatric optic pathway gliomas (OPGs), data describing the methods of diagnosis and treatment for OPGs are limited in the modern era. This retrospective study aims to provide an epidemiological overview in the pediatric population and an update on eye care resource utilization in OPG patients using big data analysis.
Methods:
Using the OptumLabs Data Warehouse, 9-11 million children from 2016 to 2021 assessed the presence of an OPG claim. This data set was analyzed for demographic distribution data and clinical data including average ages for computed tomography (CT), MRI, strabismus, and related treatment (surgery, chemotherapy, and radiation), as well as yearly rates for optical coherence tomography (OCT) and visual field (VF) examinations.
Results:
Five hundred fifty-one unique patients ranging in age from 0 to 17 years had an OPG claim, with an estimated prevalence of 4.6-6.1 per 100k. Among the 476 OPG patients with at least 6 months of follow-up, 88.9% had at least one MRI and 15.3% had at least one CT. Annual rates for OCT and VF testing were similar (1.26 vs 1.35 per year), although OCT was ordered for younger patients (mean age = 9.2 vs 11.7 years, respectively). During the study period, 14.1% of OPG patients had chemotherapy, 6.1% had either surgery or radiation, and 81.7% had no treatment.
Conclusions:
This study updates OPG demographics for the modern era and characterizes the burden of the treatment course for pediatric OPG patients using big data analysis of a commercial claims database. OPGs had a prevalence of about 0.005% occurring equally in boys and girls. Most did not receive treatment, and the average child had at least one claim for OCT or VF per year for clinical monitoring. This study is limited to only commercially insured children, who represent approximately half of the general child population.
